These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 35102110)

  • 1. SPP1 in infliximab resistant ulcerative colitis and associated colorectal cancer: an analysis of differentially expressed genes.
    Giannos P; Triantafyllidis KK; Giannos G; Kechagias KS
    Eur J Gastroenterol Hepatol; 2022 Jun; 34(6):598-606. PubMed ID: 35102110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Artificial Neural Network Analysis-Based Immune-Related Signatures of Primary Non-Response to Infliximab in Patients With Ulcerative Colitis.
    Chen X; Jiang L; Han W; Bai X; Ruan G; Guo M; Zhou R; Liang H; Yang H; Qian J
    Front Immunol; 2021; 12():742080. PubMed ID: 34992592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Focusing on non-responders to infliximab with ulcerative colitis, what can we do first and next?
    Pu D; Wang P; Wang X; Tian Y; Gong H; Ma X; Li M; Zhang D
    Int Immunopharmacol; 2024 Nov; 141():112943. PubMed ID: 39191122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Normalization of mucosal tumor necrosis factor-α: A new criterion for discontinuing infliximab therapy in ulcerative colitis.
    Olsen T; Rismo R; Gundersen MD; Paulssen EJ; Johnsen K; Kvamme JM; Goll R; Florholmen J
    Cytokine; 2016 Mar; 79():90-5. PubMed ID: 26775117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Infliximab in ulcerative colitis: real-life analysis of factors predicting treatment discontinuation due to lack of response or colectomy: ECIA (ACAD Colitis and Infliximab Study).
    Fernández-Salazar L; Muñoz F; Barrio J; Muñoz C; Pajares R; Rivero M; Prieto V; Legido J; Bouhmidi A; Herranz M; Fernández N; Sánchez-Ocaña R; Joao D; Santos F
    Scand J Gastroenterol; 2016; 51(2):186-95. PubMed ID: 26200929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Long-term follow-up of inflammatory bowel disease patients receiving anti-tumor necrosis factor-alpha therapy].
    Bacsur P; Skribanek S; Milassin Á; Farkas K; Bor R; Fábián A; Rutka M; Bálint A; Szántó KJ; Tóth T; Nagy F; Szepes Z; Boda K; Molnár T
    Orv Hetil; 2020 Nov; 161(47):1989-1994. PubMed ID: 33226355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repeated intensified infliximab induction - results from an 11-year prospective study of ulcerative colitis using a novel treatment algorithm.
    Johnsen KM; Goll R; Hansen V; Olsen T; Rismo R; Heitmann R; Gundersen MD; Kvamme JM; Paulssen EJ; Kileng H; Johnsen K; Florholmen J
    Eur J Gastroenterol Hepatol; 2017 Jan; 29(1):98-104. PubMed ID: 27749779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identified potential biomarkers may predict primary nonresponse to infliximab in patients with ulcerative colitis.
    Zhang J; Wu X; Wei S; Liu C; Wang X; Dong W
    Autoimmunity; 2022 Dec; 55(8):538-548. PubMed ID: 35876170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distribution and Cytokine Profile of Peripheral B Cell Subsets Is Perturbed in Pediatric IBD and Partially Restored During a Successful IFX Therapy.
    Schnell A; Schwarz B; Wahlbuhl M; Allabauer I; Hess M; Weber S; Werner F; Schmidt H; Rechenauer T; Siebenlist G; Kaspar S; Ehrsam C; Rieger D; Rückel A; Metzler M; Christoph J; Woelfle J; Rascher W; Hoerning A
    Inflamm Bowel Dis; 2021 Jan; 27(2):224-235. PubMed ID: 32185399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histological healing after infliximab induction therapy in children with ulcerative colitis.
    Wiernicka A; Szymanska S; Cielecka-Kuszyk J; Dadalski M; Kierkus J
    World J Gastroenterol; 2015 Oct; 21(37):10654-61. PubMed ID: 26457025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. C-reactive protein level at 2 weeks following initiation of infliximab induction therapy predicts outcomes in patients with ulcerative colitis: a 3 year follow-up study.
    Iwasa R; Yamada A; Sono K; Furukawa R; Takeuchi K; Suzuki Y
    BMC Gastroenterol; 2015 Aug; 15():103. PubMed ID: 26271624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Ulcerative Colitis Response Index for Detection of Mucosal Healing in Patients Treated With Anti-tumour Necrosis Factor.
    de Bruyn M; Ringold R; Martens E; Ferrante M; Van Assche G; Opdenakker G; Dukler A; Vermeire S
    J Crohns Colitis; 2020 Feb; 14(2):176-184. PubMed ID: 31628842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis-results from a multicenter prospective randomized controlled trial and its post hoc analysis.
    Kobayashi T; Suzuki Y; Motoya S; Hirai F; Ogata H; Ito H; Sato N; Ozaki K; Watanabe M; Hibi T
    J Gastroenterol; 2016 Mar; 51(3):241-51. PubMed ID: 26162647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative Effectiveness of Infliximab and Adalimumab in Crohn's Disease and Ulcerative Colitis.
    Ananthakrishnan AN; Cagan A; Cai T; Gainer VS; Shaw SY; Savova G; Churchill S; Karlson EW; Kohane I; Liao KP; Murphy SN
    Inflamm Bowel Dis; 2016 Apr; 22(4):880-5. PubMed ID: 26933751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distinct Anti-IFI16 and Anti-GP2 Antibodies in Inflammatory Bowel Disease and Their Variation with Infliximab Therapy.
    Caneparo V; Pastorelli L; Pisani LF; Bruni B; Prodam F; Boldorini R; Roggenbuck D; Vecchi M; Landolfo S; Gariglio M; De Andrea M
    Inflamm Bowel Dis; 2016 Dec; 22(12):2977-2987. PubMed ID: 27636380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genes associated with intestinal permeability in ulcerative colitis: changes in expression following infliximab therapy.
    Toedter G; Li K; Sague S; Ma K; Marano C; Macoritto M; Park J; Deehan R; Matthews A; Wu GD; Lewis JD; Arijs I; Rutgeerts P; Baribaud F
    Inflamm Bowel Dis; 2012 Aug; 18(8):1399-410. PubMed ID: 22223479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Construction of a molecular inflammatory predictive model with histone modification-related genes and identification of CAMK2D as a potential response signature to infliximab in ulcerative colitis.
    Ye S; Lyu Y; Chen L; Wang Y; He Y; Li Q; Tian L; Liu F; Wang X; Ai F
    Front Immunol; 2023; 14():1282136. PubMed ID: 38274809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Evaluation of efficacy and comparative frequency of adverse events in patients with ulcerative colitis receiving the original infliximab and its biosimilar. One year of observation].
    Knyazev OV; Shkurko TV; Kagramanova AV; Lishchinskaya AA; Zvyaglova MY; Korneeva IA; Babayan AF; Parfenov AI
    Ter Arkh; 2019 Aug; 91(8):41-46. PubMed ID: 32598753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cell division control 42 elevates during infliximab therapy, and its increment relates to treatment response in ulcerative colitis patients.
    Liu L; Liu Q; Chang J; Dong X; Ma W
    J Clin Lab Anal; 2022 Jun; 36(6):e24477. PubMed ID: 35527674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical outcome after discontinuation of infliximab in patients with ulcerative colitis in deep remission].
    Muñoz Villafranca C; Bravo Rodríguez MT; Ortiz de Zárate J; Arreba González P; García Kamiruaga I; Heras Martín JI; Cabezudo Gil P; Orive Cura V
    Gastroenterol Hepatol; 2016; 39(7):442-8. PubMed ID: 26948837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.